Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Immunotherapy

Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL

Nature Reviews Clinical Oncology volume 20, pages 5–6 (2023)Cite this article

Subjects

CAR T cell therapy has altered the natural history of relapsed and/or refractory diffuse large B cell lymphoma (DLBCL). However, the availability of multiple products has created provider uncertainty regarding treatment selection and the need to balance toxicity and efficacy. In a retrospective analysis, the authors suggest that axicabtagene ciloleucel might be superior to tisagenlecleucel. However, several questions remain unresolved.

Refers to Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med. 28, 2145–2154 (2022).

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

References

  1. Hu, Z. H., Peter Gale, R. & Zhang, M. J. Direct adjusted survival and cumulative incidence curves for observational studies. Bone Marrow Transplant. 55, 538–543 (2020).

    Article  Google Scholar 

  2. Khera, N. et al. Comparison of characteristics and outcomes of trial participants and nonparticipants: example of blood and marrow transplant clinical trials network 0201 trial. Biol. Blood Marrow Transplant. 21, 1815–1822 (2015).

    Article  Google Scholar 

  3. Bachy, E. et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat. Med. 28, 2145–2154 (2022).

    Article  CAS  Google Scholar 

  4. Brookhart, M. A. et al. Variable selection for propensity score models. Am. J. Epidemiol. 163, 1149–1156 (2006).

    Article  Google Scholar 

  5. Bethge, W. A. et al. GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140, 349–358 (2022).

    CAS  Google Scholar 

  6. Gauthier, J. et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. Blood 139, 3722–3731 (2022).

    Article  CAS  Google Scholar 

  7. Riedell, P. A. et al. Patterns of use, outcomes, and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed/refractory aggressive B cell lymphomas. Transplant Cell Ther. 28, 669–676 (2022).

    Article  Google Scholar 

  8. Oluwole, O. O. et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br. J. Haematol. 194, 690–700 (2021).

    Article  CAS  Google Scholar 

  9. NICE. Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years. nice.org.uk, https://www.nice.org.uk/guidance/ta554 (21 December 2022).

  10. ICER. Leukemia and Lymphoma. icer.org https://icer.org/assessment/leukemia-and-lymphoma-2018 (March 2018).

Download references

Author information

Authors and Affiliations

  1. Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA

    Richard T. Maziarz

  2. Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA

    Jordan Gauthier

  3. Department of Medicine, University of Washington, Seattle, WA, USA

    Jordan Gauthier

Authors
  1. Richard T. Maziarz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jordan Gauthier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Richard T. Maziarz.

Ethics declarations

Competing interests

R.T.M. has acted as a consultant and/or adviser of Artiva Therapeutics, Bristol-Myers Squibb/Celgene, CRISPR Therapeutics, Incyte, Kite and Novartis and has received research funding from BMS and Novartis. J.G. has acted as a consultant and/or adviser of Janssen, Kite Pharma, Legend Biotech and MorphoSys and has received research funding from Angiocrine Bioscience, Celgene (a BMS company), Juno Therapeutics (a BMS company) and Sobi.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Maziarz, R.T., Gauthier, J. Clash of the titans: axi-cel versus tisa-cel for advanced-stage DLBCL. Nat Rev Clin Oncol 20, 5–6 (2023). https://doi.org/10.1038/s41571-022-00711-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41571-022-00711-4

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing